Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma
Status:
Completed
Trial end date:
2018-11-30
Target enrollment:
Participant gender:
Summary
The purpose of the trial was to evaluate efficacy and safety of QMF149 150/80 microgram o.d.
delivered via Concept1 compared to MF 200 microgram o.d., delivered via Twisthaler® in terms
of lung function and symptom control in poorly (ie inadequately) controlled asthma patients.
This study was to assess contribution of LABA as an add-on therapy to low dose ICS
monotherapy.